Aptose Biosciences Inc. (TSX: APS)

Market Cap	21.73M
Revenue (ttm)	n/a
Net Income (ttm)	-48.36M
Shares Out	59.52M
EPS (ttm)	-3.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,356
Open	0.360
Previous Close	0.355
Day's Range	0.300 - 0.365
52-Week Range	0.190 - 3.480
Beta	1.36
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 36
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: APS

Financial Performance

Financial numbers in USD